Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · June 25, 2023

Early Rituximab Treatment Reduces Long-Term Disability in Patients With Aquaporin-4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder

Journal of Neurology, Neurosurgery, and Psychiatry


Additional Info

Journal of Neurology, Neurosurgery, and Psychiatry
Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum
J. Neurol. Neurosurg. Psychiatr. 2023 Jun 02;[EPub Ahead of Print], SY Park, YN Kwon, S Kim, SH Kim, JK Kim, JS Kim, TS Nam, YG Min, KS Park, JS Park, JM Seok, JJ Sung, E Sohn, KJ Shin, JH Shin, HY Shin, SI Oh, J Oh, BA Yoon, S Lee, JM Lee, HL Lee, K Choi, SY Huh, MJ Jang, JH Min, BJ Kim, SM Kim

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading